Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Andersson, U, Smith, D, Jeyakumar, M, Butters, T, Borja, M, Dwek, R, Platt, F
Format:	Journal article
Sprache:	English
Veröffentlicht:	2004

Ähnliche Einträge

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
von: Ulrika Andersson, et al.
Veröffentlicht: (2004-08-01)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
von: Jeyakumar, M, et al.
Veröffentlicht: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
von: Andersson, U, et al.
Veröffentlicht: (2000)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
von: Baek, R, et al.
Veröffentlicht: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
von: Baek, R, et al.
Veröffentlicht: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
von: Platt, F, et al.
Veröffentlicht: (2003)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
von: Jeyakumar, M, et al.
Veröffentlicht: (2001)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
von: Kasperzyk, J, et al.
Veröffentlicht: (2004)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
von: Kasperzyk, J, et al.
Veröffentlicht: (2004)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
von: Baek, R, et al.
Veröffentlicht: (2005)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
von: Lowe, J, et al.
Veröffentlicht: (2005)

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
von: Lachmann, R, et al.
Veröffentlicht: (2006)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
von: Awan, F, et al.
Veröffentlicht: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
von: Elliot-Smith, E, et al.
Veröffentlicht: (2008)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
von: Pelled, D, et al.
Veröffentlicht: (2003)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
von: Kaya, E, et al.
Veröffentlicht: (2020)

New developments in treating glycosphingolipid storage diseases.
von: Platt, F, et al.
Veröffentlicht: (2005)

Substrate reduction therapy
von: Platt, F, et al.
Veröffentlicht: (2007)

Substrate reduction therapy.
von: Platt, F, et al.
Veröffentlicht: (2008)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
von: Rountree, J, et al.
Veröffentlicht: (2009)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
von: Denny, C, et al.
Veröffentlicht: (2010)

Infantile Sandhoff's disease
von: K Sass, et al.
Veröffentlicht: (2009-08-01)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
von: Jeyakumar, M, et al.
Veröffentlicht: (2002)

Storage solutions: treating lysosomal disorders of the brain.
von: Jeyakumar, M, et al.
Veröffentlicht: (2005)

An inducible mouse model of late onset Tay-Sachs disease.
von: Jeyakumar, M, et al.
Veröffentlicht: (2002)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
von: Richardson, K, et al.
Veröffentlicht: (2016)

Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model
von: Evan Woodley, et al.
Veröffentlicht: (2019-03-01)

Dysregulation of the NLRP3 Inflammasome and Promotion of Disease by IL-1β in a Murine Model of Sandhoff Disease
von: Nick Platt, et al.
Veröffentlicht: (2025-01-01)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
von: te Vruchte, D, et al.
Veröffentlicht: (2010)

An Inducible Mouse Model of Late Onset Tay–Sachs Disease
von: Mylvaganam Jeyakumar, et al.
Veröffentlicht: (2002-08-01)

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
von: Andersson, U, et al.
Veröffentlicht: (2004)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
von: Platt, F, et al.
Veröffentlicht: (2001)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
von: van der Spoel, A, et al.
Veröffentlicht: (2002)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
von: Karen M Ashe, et al.
Veröffentlicht: (2011-01-01)

Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics
von: Emmanuelle Lecommandeur, et al.
Veröffentlicht: (2020-12-01)

Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation.
von: Mellor, H, et al.
Veröffentlicht: (2003)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
von: Jeyakumar, M, et al.
Veröffentlicht: (2003)

Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease.
von: Yasuhiro Ogawa, et al.
Veröffentlicht: (2013-01-01)

Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage.
von: Yasuhiro Ogawa, et al.
Veröffentlicht: (2017-01-01)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
von: Priestman, D, et al.
Veröffentlicht: (2008)